缬沙坦联合螺内酯治疗方案对顽固性心衰的疗效及对凝血功能、心功能的影响

摘要/Abstract

摘要： 目的探讨缬沙坦联合螺内酯治疗方案对顽固性心衰疗效及对凝血功能、心功能的影响。方法选择2019年1月~2020年12月赤峰市肿瘤医院收治的80例顽固性心衰患者为观察对象,利用随机数表法分为对照组和试验组,每组40例。对照组口服缬沙坦治疗,试验组在上述治疗措施基础上接受螺内酯治疗,对比两组临床治疗有效率、凝血指标、心功能、ET-1和NO水平以及生活质量改善情况。结果试验组总有效率明显高于对照组,差异有统计学意义（P<0.05）;治疗后,试验组D-二聚体（D-D）、血管性血友病因子（vWF）水平明显低于对照组,试验组活化部分凝血活酶时间（APTT）水平则明显高于对照组,试验组左室射血分数（LVEF）、每博输出量（SV）水平明显高于对照组,试验组心率（HR）水平明显低于对照组,差异有统计学意义（P<0.05）;治疗后,试验组ET-1水平显著低于对照组,而其NO水平则明显高于对照组,差异有统计学意义（P<0.05）;治疗后,试验组生理功能、心理状态、物质生活和社会关系方面的生活质量评分均高于对照组,差异有统计学意义（P<0.05）。结论顽固性心衰患者实施缬沙坦联合螺内酯方案治疗,具有较高的治疗有效性,且患者治疗后凝血功能指标、心功能和ET-1和NO水平明显改善,有利于提高患者的生活质量,应用价值较高。

关键词: 缬沙坦, 螺内酯, 顽固性心衰, 凝血功能, 心功能

Abstract: Objective To investigate the effects of valsartan combined with spironolactone on the treatment of intractable heart failure, coagulation function and cardiac function. Methods Eighty patients with intractable heart failure at the Department of Cardiology, Chifeng Cancer Hospital from January 2019 to December 2020 were involved and randomly divided into control group and experimental group, and each group contained 40 patients. The control group were treated with valsartan, while experimental group was also administrated with spironolactone in addition to valsartan. Response rated of different therapeutic schemes, and the improvement of coagulation indexes, cardiac function, ET-1 and NO levels and improvement of life quality from patients were compared herein. Results Response rate of experimental group was higher than control group,the difference was statistically significant (P<0.05). At the same time, after treatment the levels of D-dimer (D-D) and von Willebrand factor (vWF) in the control group were significantly lower than those in the control group. But the level of activated partial thromboplastin time (APTT) was significantly higher than that of the control group, the levels of left ventricular ejection fraction (LVEF) and output per stroke (SV) were significantly higher than those of the control group, and the level of heart rate (HR) was significantly lower than that of the control group. There was statistically significant difference between the two groups (P<0.05). After treatment, the level of ET-1 in the experimental group was significantly lower than that in the control group, while the level of NO in the experimental group was statistically significantly higher than that in the control group (P<0.05). The scores of physical function, psychological state, material life and life quality of social relations in the experimental group were higher than those in the control group after clinical treatment, and the difference was statistically significant (P<0.05). Conclusion Valsartan combined with spironolactone in the treatment of patients with intractable heart failure possessed high therapeutic efficacy, and the indexes of coagulation function, cardiac function and the levels of ET-1 and NO were significantly improved after treatment, which showed the potential to improve the life quality of patients and afforded high value of popularization and application.

Key words: Valsartan, spironolactone, intractable heart failure, coagulation function, cardiac function

中图分类号:

R541.6

刘艳艳. 缬沙坦联合螺内酯治疗方案对顽固性心衰的疗效及对凝血功能、心功能的影响[J]. 中华养生保健, 2022, 40(17): 7-10.

LIU Yan-yan. Effects of Valsartan Combined with Spironolactone on Intractable Heart Failure,Coagulation Function and Cardiac Function[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(17): 7-10.

参考文献

[1] 彭卫平. 美托洛尔与螺内酯联合治疗慢性心力衰竭对患者心功能的影响[J].基层医学论坛,2019,23(32):4635-4636.
[2] 美国心脏病学会.2001年美国心脏病学会(ACC),美国心脏协会(AHA)成人慢性心衰的诊断和治疗指南[J].肇庆医学,2005,(1):6-10.
[3] 占达良,胡少敏.螺内酯治疗老年冠心病并慢性心力衰竭患者的疗效及对脑钠肽、心功能的影响[J].心血管康复医学杂志,2019, 28(3):326-329.
[4] 邓飞,邢风雷,吴娟鸽.厄贝沙坦联合螺内酯治疗慢性心力衰竭患者的临床疗效及其对炎性因子、自主神经功能的影响研究[J].实用心脑肺血管病杂志,2019,27(2):89-92.
[5] 鲁志科,孙榕.不同剂量螺内酯对缺血性心肌病心力衰竭患者心脏结构和功能的影响[J].河北医科大学学报,2018,39(9):1002-1006.
[6] 于虹,赵天淼,刘凯.沙库巴曲缬沙坦钠片治疗老年慢性心力衰竭的效果[J].中国老年学杂志,2019,39(15):3620-3622.
[7] 符善超. 缬沙坦联合美托洛尔和螺内酯治疗慢性心力衰竭的临床疗效分析[J].中国继续医学教育,2016,8(21):144-145.
[8] 陈华. 缬沙坦、美托洛尔缓释片联合螺内酯治疗慢性心力衰竭的临床观察[J].世界临床医学,2016,10(22):103-104.
[9] 陈华. 缬沙坦、美托洛尔缓释片联合螺内酯治疗慢性心力衰竭的临床观察[J].世界临床医学,2016,10(22):103-104.
[10] 侯伊玲,储毓舜,景秀绒.缬沙坦联用螺内酯对慢性心力衰竭患者心肌重塑的影响[J].武警后勤学院学报(医学版),2010,19(3):178-180.
[11] 袁盛健. 多巴胺联合硝普钠治疗心梗后左心衰的效果分析[J].中国现代药物应用,2021,15(2):109-111.
[12] 陈婷婷. 硝普钠、多巴胺和呋塞米联合应用治疗顽固性心衰的疗效观察[J].中国现代药物应用,2021,15(16):92-94.
[13] Kolkhof P, Joseph A, Kintscher U.Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy[J].Pharmacol Res.,2021,172:105859.
[14] 王姝. 多巴胺结合硝普钠持续静脉泵入治疗老年顽固性心衰的疗效及对患者心功能的影响[J].中外医疗,2021,40(20):113-116.
[15] 石淑静,李今朝.小剂量沙库巴曲缬沙坦对顽固性心衰患者的疗效和安全性分析[J].中国社区医师,2021,37(17):86-88.
[16] 徐建辉. 沙库巴曲缬沙坦治疗射血分数保留的顽固性心衰1例[J].慢性病学杂志,2021,22(6):978-980.